Piper Downgrades Zimmer to Neutral, Cites Lack of Catalysts

Seeking Alpha00:35

Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive in

BenzingaJul 1 23:00

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price target.

BenzingaJul 1 21:32

Johnson & Johnson Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 46.83% Cantor Fitzgerald $215 → $215 Reiterates Overweight → Overweight 06/25/2024 46.83% Canto

BenzingaJul 1 21:31

Express News | U.S. Food and Drug Administration (FDA) Approves Foundationone Liquid Cdx as a Companion Diagnostic for Akeega (Niraparib and Abiraterone Acetate) for Patients With Brca-Positive Metastatic Castration-Resistant Prostate Cancer

BreakingsJul 1 19:04

Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $167

Morgan Stanley analyst Terence Flynn maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and adjusts the target price from $168 to $167.According to TipRanks data, the analyst has a success rate

Futu NewsJul 1 18:31 · Ratings